Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Pituitary adenomas in mice transgenic for growth hormone-releasing hormone.

Authors: Asa, SL  Kovacs, K  Stefaneanu, L  Horvath, E  Billestrup, N  Gonzalez-Manchon, C  Vale, W 
Citation: Asa SL, etal., Endocrinology. 1992 Nov;131(5):2083-9.
Pubmed: (View Article at PubMed) PMID:1425411
DOI: Full-text: DOI:10.1210/endo.131.5.1425411

It has been shown that mice transgenic for human GH-releasing hormone (GRH) develop hyperplasia of pituitary somatotrophs, lactotrophs, and mammosomatotrophs, cells capable of producing both GH and PRL, by 8 months of age. We now report that GRH transgenic mice 10-24 months of age develop pituitary adenomas, which we characterized by histology, immunohistochemistry, in situ hybridization, and electron microscopy. Of 13 animals examined, all developed GH-immunoreactive neoplasms that had diffuse positivity for GH mRNA by in situ hybridization. Eleven also contained PRL immunoreactivity; in situ hybridization demonstrated focal PRL mRNA in 3 of 5 immunohistochemically positive tumors. Alpha-Subunit was positive by immunohistochemistry in 8 adenomas, and TSH beta was localized in tumor cells of 5 adenomas. The adenomas had variable ultrastructural appearances, ranging from cells that resembled somatotrophs or mammosomatotrophs to cells with features of the glycoprotein hormone cell line. These findings provide conclusive evidence that protracted GRH stimulation of secretory activity can result in proliferation, hyperplasia, and adenoma of adenohypophysial cells.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 5687177
Created: 2012-02-03
Species: All species
Last Modified: 2012-02-03
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.